Abstract | AIMS: METHODS: The study included 698 patients with IDA on dialysis or with nondialysis chronic kidney disease (CKD) stages 3 - 5 designated by their physicians for treatment with iron isomaltoside. Data were recorded at baseline and after 3 and 9 months. Effectiveness data included measurement of hemoglobin (Hb), hematocrit, i- iron, transferrin saturation (TSAT), and i- ferritin. Safety data included adverse events and safety laboratory variables. RESULTS: Following administration of a mean cumulative dose of 2,574 mg isomaltoside over 9 months, initial average Hb increased from 11.0 g/dL to 11.6 g/dL, TSAT from 19.4% to 28.3%, and i- ferritin from 320 µg/L to 642 µg/L, demonstrating a positive effect of iron isomaltoside on iron deficiency. In addition, there was a significant reduction in the use of erythropoiesis-stimulating agents (ESAs) (regarding epoetin α, initial mean dose 40,688 IU/month, final dose 35,665 IU/month, -13.7%, p < 0.001). No drug-related adverse events were reported. Furthermore, safety parameters including i- phosphate indicated no abnormal changes. CONCLUSIONS:
Iron isomaltoside demonstrated very good effectiveness and tolerability in patients with stage 3 - 5 CKD, including an ESA saving effect.
.
|
Authors | Patrick Biggar, Frank Leistikow, Andreas Walper |
Journal | Clinical nephrology
(Clin Nephrol)
Vol. 86 (2016)
Issue 12
Pg. 310-318
(12 2016)
ISSN: 0301-0430 [Print] Germany |
PMID | 27737531
(Publication Type: Journal Article, Observational Study)
|
Chemical References |
- Disaccharides
- Ferric Compounds
- Hematinics
- Hemoglobins
- iron isomaltoside 1000
|
Topics |
- Aged
- Aged, 80 and over
- Anemia, Iron-Deficiency
(blood, drug therapy, etiology)
- Disaccharides
(adverse effects, therapeutic use)
- Female
- Ferric Compounds
(adverse effects, therapeutic use)
- Hematinics
(therapeutic use)
- Hemoglobins
(metabolism)
- Humans
- Kidney Failure, Chronic
(complications, therapy)
- Male
- Middle Aged
- Prospective Studies
- Renal Dialysis
|